EMPA-LIVERNCT07915596
Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
StatusCompleted
PhaseNot specified
Primary completion
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Change in BARD Score
Timeframe: 12 weeks after randomization
Change in liver fat
Timeframe: 24 weeks after randomization
Arms and interventions
Empagliflozin 10 and 15 mg + Standard Therapy
Standard Therapy Alone (Control)
Drugs: Empagliflozin 10/15 mg administered orally once daily in addition to standard treatment for type 2 diabetes mellitus.
Sites
1 site in 1 country
- Department of MedicineDhaka, Bangladesh